30 closest matches · ranked by relevance
Arthroplasty, Replacement, Knee · Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 188; 219; 163 Participants — p=0.0234
Venous Thromboembolism · Arthroplasty
Primary: Deep Vein Thrombosis — 0; 1 Participants
Arthroplasty, Replacement, Knee
Primary: Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated) — 7; 30; 27; 14 Participants
Thromboembolism · Arthroplasty, Replacement, Hip
Primary: Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 53; 75; 60 Participants — p=0.5648
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects…
Venous Thromboembolism · Haemorrhage
Primary: Incidence of Symptomatic Venous Thromboembolism Plus Asymptomatic Proximal Vein Thrombosis and All-cause Mortality — 1; 7 participants — p=0.03
Venous Thromboembolism
Primary: Occurrence of Symptomatic Venous Thromboembolic Events — 19; 5 participants
Venous Thromboembolism
Primary: Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin) — 17.2; 22.2 percentage of participants
Venous Thromboembolism
Primary: Incidence of Subjects With Venous Thromboembolism Events. — 7.4; 13.9 percent of participants with VTE events — p=<0.001
Venous Thrombosis
Primary: Deep Vein Thrombosis — 2 Participants
Arthroplasty, Replacement · Thromboembolism
Primary: Percentage of Patients With Major Bleeding Events (MBE) During Treatment Period — 0.72 Percentage of participants
Venous Thromboembolism
Primary: Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of…
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
Thromboembolism
Primary: Incidence of Adjudicated Venous Thromboembolism (VTE) — 20; 15.4; 10 Percentage of Participants
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period — 15.06; 24.37 Percentage of events/patients…
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Primary: Number of Participants With Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]- Adjudicated) — 2; 0; 5; 1 Participants
Venous Thromboembolism · Deep Vein Thrombosis · Total Knee Arthroplasty
Primary: Proportion of Subjects With Venous Thromboembolism Events. — 29.5; 26.1; 12.5; 9.1 percentage of participants — p=<0.001
Venous Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 61; 69 Participants — p=< 0.0001
Arthroplasty, Replacement, Knee · Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 183; 213; 193 Participants — p=0.6648
Primary Total Hip and Knee Arthroplasty
Primary: Blood Loss — 6; 1 participants
Arthroplasty, Replacement, Knee · Venous Thrombosis
Primary: Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period…
Venous Thromboembolism
Primary: Number of Participants With Venous Thromboembolic (VTE) Events — 86; 49; 39; 47 participants — p=<0.0001
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137
Arthroplasty, Replacement · Prevention of Venous Thromboembolism · Moderate Renal Impairment (CrCl 30-50 mL/Min)
Primary: Dabigatran Concentration in Plasma, Estimated From Local Hemoclot® — 136 measurements estimated as above LLOQ
Venous Thromboembolism
Primary: Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) — 7.1; 17.2 percentage of participants
Arthritis · Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa) — 1.66; 1.83 IU/ml — p=.008
Arthroplasty, Replacement · Thromboembolism
Primary: Percentage of Patients With Major Bleeding Events (MBE) — 2.10 percentage of participants
Prevention · Venous Thromboembolism
Primary: Incidence of Subjects With Venous Thromboembolism Events — 2.4; 6.9 percentage of subjects with vte events — p=<0.001
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
Thromboembolism
Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 27; 34; 32 Participants — p=<0.0001